SpikImm, co-founded by Truffle Capital and Institut Pasteur is a clinical-stage biopharma company that develops mAbs for the prevention of severe infectious diseases affecting immunocompromised (IC) patients. SpikImm’s portfolio include SPK002M, a highly potent mAb active across all existing SARS-CoV-2 variants. SpikImm is currently expanding its portfolio with additional anti-infective mAbs, also developed in prevention of infectious diseases affecting immunocompromised patients.
See website![logo_spikimm_1.jpg](/assets/h90-q90-p1/bc87883b/logo_spikimm_1.jpg)
![](/themes/TruffleTheme/static/img/fluid-bg/fluid-bg_2x_p4u3tv_c_scale,w_2880.jpg)
Synoptical view
- First investment date
- 2021
![adobestock_338066476_tetiere_2.jpeg](/assets/f1413x672-q85-p1/9c099fed/adobestock_338066476_tetiere_2.jpeg)